Status:
COMPLETED
Risk of Developing Dementia and Associated Factors in Patients With Normal Brain FDG PET
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Neurodegenerative Diseases
Cognitive Disorder
Eligibility:
All Genders
18+ years
Brief Summary
Brain 18F-FDG PET (positron emission tomography) is recognised as having a good negative predictive value in the search for a neurodegenerative origin of cognitive disorders. Indeed, a ratio of 0.1 on...
Detailed Description
Brain 18F-FDG PET is known to have a good negative predictive value in the search for a neurodegenerative origin to cognitive disorders. Indeed, a ratio of 0.1 on the occurrence of worsening cognitive...
Eligibility Criteria
Inclusion
- Adult patient who had a PET scan with 18F-FDG in the brain at least 3 years previously
- Patients referred for PET scans for cognitive disorders, whether or not they have been diagnosed
- Patients referred for PET scans for neurodegenerative pathology 18F-FDG PET brain scan interpreted as normal
Exclusion
- Brain 18F-FDG PET scan considered abnormal after semi-quantitative analysis
Key Trial Info
Start Date :
January 20 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04804722
Start Date
January 20 2022
End Date
July 1 2023
Last Update
July 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nuclear medicine Department CHRU de NANCY
Vandœuvre-lès-Nancy, France, 54511